Yup, I think that’s one of the right questions to ask. I expect that there’s a real market inefficiency somewhere in there, but it’s definitely the sort of thing I’d recommend actively investigating while on the ground. If it turns out there’s not an inefficiency in distribution (or end-use), then yeah, just drop the load on someone. Ideally, one figures out exactly where the inefficiency is and can then pivot to a much higher-impact strategy.
It also could be that the market is efficient & the people of the Sahel have better things to spend their money on than antibiotics; i.e. you’d be better off giving them money than antibiotics. Or whatever. I’d be interested to see more argument that they need that stuff in particular, rather than just money.
Yup, I think that’s one of the right questions to ask. I expect that there’s a real market inefficiency somewhere in there, but it’s definitely the sort of thing I’d recommend actively investigating while on the ground. If it turns out there’s not an inefficiency in distribution (or end-use), then yeah, just drop the load on someone. Ideally, one figures out exactly where the inefficiency is and can then pivot to a much higher-impact strategy.
It also could be that the market is efficient & the people of the Sahel have better things to spend their money on than antibiotics; i.e. you’d be better off giving them money than antibiotics. Or whatever. I’d be interested to see more argument that they need that stuff in particular, rather than just money.